From: Novel drugs that target the metabolic reprogramming in renal cell cancer
Drug | Target | Clinical stage | RCC |
---|---|---|---|
2DG | Glucose | Phase 2 | n.a. |
Lonidamine | HK | Phase 2 | Negative |
Dichloroacetate (DCA) | PDK | Phase 3 | n.a. |
Polyphenon E | LDH-A | Phase 1 | n.a. |
FK866 | GAPDH | Phase 1 | n.a. |
AT-101 | LDH-A | Phase 2 | n.a. |
PEG-ADI | Arginase 1 | Phase 3 | n.a. |
Indoximod | LAT1 | Phase 2 | n.a. |
Acivicin | Glutamine | Phase 2 | Negative |
6-Diazo-5-oxo-l-norleucine (DON) | Glutamine | Phase 2 | n.a. |
Orlistat | FASN | Phase 1 | n.a. |
Metformin | GPDH | Phase 3 | n.a. |
NVP-BEZ235 | PI3K/mTOR | Phase 2 | n.a. |
GDC-0980 (apitolisib) | PI3K/mTOR | Phase 2 | n.a. |
SF1126 | PI3K | Phase 1 | n.a. |
BYL719 | P110a | Phase 2 | n.a. |
MLN1117 | P110a | Phase 2 | n.a. |
AZD8186 | p110β | Phase 1 | n.a. |
GSK2636771 | p110β | Phase 2 | n.a. |
SAR260301 | p110β | Phase 1 | n.a. |
Perifosine | Akt | Phase 2 | Negative |
MK-2206 | Akt | Phase 2 | n.a. |
GSK690693 | Akt | Phase 1 | n.a. |
GDC-0068 | Akt | Phase 2 | n.a. |
BEZ235 | PI3K/mTOR | Phase 2 | n.a. |
XL765 | PI3K/mTOR | Phase 1 | n.a. |
GDC0890 | PI3K/mTOR | Phase 2 | n.a. |
GSK1059615 | PI3K/mTOR | Phase 1 | n.a. |
AZD8055 | mTORC1/2 | Phase 1 | n.a. |
AZD2014 | mTORC1/2 | Phase 2 | Negative |